Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).
Matthias Holdhoff
No relevant relationships to disclose
Stuart A. Grossman
Consultant or Advisory Role - Tau Therapeutics (U)
Jeffrey G. Supko
Research Funding - Tau Therapeutics
Xiaobu Ye
No relevant relationships to disclose
Joy D. Fisher
No relevant relationships to disclose
Serena Desideri
No relevant relationships to disclose
Richard L. Wahl
No relevant relationships to disclose
David Schiff
Consultant or Advisory Role - Tau Therapeutics (U)